Nektar Therapeutics is planning to…
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate [...]
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate [...]
Scientists aren’t entirely sure what causes rosacea, or why it [...]
Sanofi is back with its second pact of the day, [...]
MapLight Therapeutics is the latest biotech to want a turn [...]
As both Novo Nordisk and Eli Lilly race to develop [...]
The FDA has approved Enhertu combined with Roche’s Perjeta as [...]
Aviceda Therapeutics has hit a snag in its goal to [...]
The FDA has signed off on Milestone Pharmaceuticals’ Cardamyst, a [...]
Fresh off a $153 million series E round, Arthrosi Therapeutics [...]
The sexually transmitted disease has become increasingly resistant to existing [...]